Cencora Inc. confirmed that specific Walgreens volume previously serviced separately from its prime vendor agreement will transition outside the company beginning July 1, 2026. Despite this operational shift, the prime vendor agreement—which constitutes the vast majority of Cencora’s business with Walgreens—remains unchanged.

The healthcare distributor reaffirmed its fiscal year 2026 adjusted diluted earnings per share (EPS) guidance range of $17.75 to $17.95. Management stated that the volume movement was fully anticipated and reflected in the company’s August 5, 2026 commentary regarding fourth-quarter expectations for its U.S. Healthcare Solutions segment.

What the Numbers Show

The stability of the EPS guidance despite the loss of certain Walgreens volumes indicates that the remaining prime vendor agreement provides sufficient scale to absorb the impact. The explicit mention that this shift was "fully contemplated" in prior August commentary suggests no new negative surprises are embedded in the current outlook, reinforcing the reliability of the $17.75-$17.95 target for investors tracking the U.S. Healthcare Solutions segment.

Cencora Inc. reported third-quarter adjusted earnings per share of $4.48, beating the consensus estimate of $4.35, while total sales rose 5.1% year-over-year to $84.754 billion, exceeding the expected $84.315 billion. The results highlight the company’s ability to drive volume growth in high-demand therapeutic areas, particularly specialty medicines and GLP-1 diabetes and weight-loss drugs, even as these segments exert pressure on gross margins. This performance underscores the effectiveness of Cencora’s pharmaceutical-centric strategy in navigating a complex pricing environment.

The U.S. Healthcare Solutions unit generated revenue of $74.9 billion, marking a 4.9% increase from the prior year period. This growth was fueled by volume gains in specialty products, health systems, and GLP-1 medications. However, the segment faced headwinds from lower manufacturer pricing, reduced sales to a primary mail-order customer, and the prior loss of an oncology client. Meanwhile, the International Healthcare Solutions unit saw revenue climb 5.9% to $7.7 billion, supported by momentum in European distribution networks and specialty logistics operations.

Profitability metrics showed significant expansion, with quarterly gross profit surging 24.1% to $3.6 billion and operating income rising 29.1% to $1.1 billion. These gains were primarily bolstered by the February 2026 acquisition of OneOncology and favorable LIFO credit movements. Despite this top-line strength, management noted that higher sales volumes of GLP-1 drugs partially squeezed overall gross margins, reflecting the trade-off between volume growth and margin dilution in this rapidly expanding category.

Robert Mauch, president and CEO of Cencora, attributed the strong performance to the company’s strategic investments. “Our third quarter results reflect the power of our pharmaceutical-centric strategy and the continued execution of our team members,” Mauch said. He emphasized that ongoing investments in specialty capabilities, digital transformation, and talent are strengthening Cencora’s position within the healthcare ecosystem and supporting sustainable long-term growth.

Looking ahead, Cencora raised its fiscal 2026 adjusted earnings guidance from a range of $17.70-$17.90 per share to $17.75-$17.95 per share, compared to the consensus estimate of $17.79. The company also affirmed its full-year 2026 sales guidance of $334.152 billion-$340.578 billion, against a consensus expectation of $337.203 billion. Management highlighted continued investments in multi-specialty clinics (MSOs) and noted strategic mergers and acquisitions as key priorities for capital deployment.

What the Numbers Show

The divergence between revenue growth and margin pressure illustrates the structural shift in Cencora’s business mix. While gross profit surged 24.1%, the explicit mention of GLP-1 sales squeezing margins indicates that volume growth in these high-profile drugs comes with lower profitability per unit compared to traditional generics. The acquisition of OneOncology appears to be a key driver of immediate profitability gains, suggesting that strategic M&A is currently more impactful than organic margin expansion in offsetting pricing headwinds.

At the time of publication, Cencora shares were trading up 3.56% at $317.36, reflecting investor confidence in the company’s guidance raise and operational execution.